UK Biopharmaceuticals Market

ID: MRFR/Pharma/49166-HCR
200 Pages
Nidhi Mandole
Last Updated: April 06, 2026
UK Biopharmaceuticals Market Research Report: Size, Share, Trend Analysis By Product Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cellular Therapies), By Applications (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By End-use (Hospitals, Biotechnology Companies, Pharmaceutical Companies), and By Route of Administration (Intravenous, Subcutaneous, Intramuscular) - Growth Outlook & Industry Forecast 2025 To 2035
UK Biopharmaceuticals Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.21%
2024 Market Size$ 15.73 Billion
2025 Market Size$ 16.39 Billion
2035 Market Size$ 24.75 Billion
Key Players
AbbVie
Amgen
Bristol-Myers Squibb
Gilead Sciences
Johnson & Johnson
Merck & Co.
Trends
  • Rise of Personalized Medicine
  • Growth of Biologics
  • Collaborative Research Initiatives
Opportunities
  • Growing Focus on Rare Diseases
  • Increasing Demand for Advanced Therapies
  • Collaboration Between Academia and Industry
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Security, Access Control and Robotics, BY Product Type (USD Billion)
      1. 4.1.1 Monoclonal Antibodies
      2. 4.1.2 Recombinant Proteins
      3. 4.1.3 Vaccines
      4. 4.1.4 Cellular Therapies
    2. 4.2 Security, Access Control and Robotics, BY Application (USD Billion)
      1. 4.2.1 Oncology
      2. 4.2.2 Autoimmune Diseases
      3. 4.2.3 Infectious Diseases
      4. 4.2.4 Cardiovascular Diseases
    3. 4.3 Security, Access Control and Robotics, BY End-use (USD Billion)
      1. 4.3.1 Hospitals
      2. 4.3.2 Biotechnology Companies
      3. 4.3.3 Pharmaceutical Companies
    4. 4.4 Security, Access Control and Robotics, BY Route of Administration (USD Billion)
      1. 4.4.1 Intravenous
      2. 4.4.2 Subcutaneous
      3. 4.4.3 Intramuscular
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AbbVie (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Amgen (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bristol-Myers Squibb (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Gilead Sciences (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Johnson & Johnson (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Merck & Co. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Novartis (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Roche (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Sanofi (FR)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
      10. 5.2.10 Takeda Pharmaceutical (JP)
        1. 5.2.10.1 Financial Overview
        2. 5.2.10.2 Products Offered
        3. 5.2.10.3 Key Developments
        4. 5.2.10.4 SWOT Analysis
        5. 5.2.10.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY PRODUCT TYPE
    3. 6.3 UK MARKET ANALYSIS BY APPLICATION
    4. 6.4 UK MARKET ANALYSIS BY END-USE
    5. 6.5 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
    9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
    12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCT TYPE, 2024 (% SHARE)
    13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
    14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 (% SHARE)
    15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 TO 2035 (USD Billion)
    16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USE, 2024 (% SHARE)
    17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USE, 2024 TO 2035 (USD Billion)
    18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY END-USE, 2025-2035 (USD Billion)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Biopharmaceuticals Market Segmentation

UK Biopharmaceuticals Market By Product Type (USD Billion, 2025-2035)

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Cellular Therapies

UK Biopharmaceuticals Market By Application (USD Billion, 2025-2035)

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases

UK Biopharmaceuticals Market By End-use (USD Billion, 2025-2035)

  • Hospitals
  • Biotechnology Companies
  • UK Biopharmaceuticals Market Companies

UK Biopharmaceuticals Market By Route of Administration (USD Billion, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Intramuscular

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.